These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1099 related articles for article (PubMed ID: 23563134)
1. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). Hijazi Z; Wallentin L; Siegbahn A; Andersson U; Christersson C; Ezekowitz J; Gersh BJ; Hanna M; Hohnloser S; Horowitz J; Huber K; Hylek EM; Lopes RD; McMurray JJ; Granger CB J Am Coll Cardiol; 2013 Jun; 61(22):2274-84. PubMed ID: 23563134 [TBL] [Abstract][Full Text] [Related]
2. High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin. Hijazi Z; Wallentin L; Siegbahn A; Andersson U; Alexander JH; Atar D; Gersh BJ; Hanna M; Harjola VP; Horowitz JD; Husted S; Hylek EM; Lopes RD; McMurray JJ; Granger CB; J Am Coll Cardiol; 2014 Jan 7-14; 63(1):52-61. PubMed ID: 24055845 [TBL] [Abstract][Full Text] [Related]
3. High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Hijazi Z; Siegbahn A; Andersson U; Granger CB; Alexander JH; Atar D; Gersh BJ; Mohan P; Harjola VP; Horowitz J; Husted S; Hylek EM; Lopes RD; McMurray JJ; Wallentin L; Circulation; 2014 Feb; 129(6):625-34. PubMed ID: 24226808 [TBL] [Abstract][Full Text] [Related]
4. Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation. Sharma A; Hijazi Z; Andersson U; Al-Khatib SM; Lopes RD; Alexander JH; Held C; Hylek EM; Leonardi S; Hanna M; Ezekowitz JA; Siegbahn A; Granger CB; Wallentin L Circulation; 2018 Oct; 138(16):1666-1676. PubMed ID: 29871978 [TBL] [Abstract][Full Text] [Related]
5. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Wallentin L; Hijazi Z; Andersson U; Alexander JH; De Caterina R; Hanna M; Horowitz JD; Hylek EM; Lopes RD; Asberg S; Granger CB; Siegbahn A; Circulation; 2014 Nov; 130(21):1847-58. PubMed ID: 25294786 [TBL] [Abstract][Full Text] [Related]
6. Usefulness of N-terminal pro-B-type natriuretic Peptide levels for stroke risk prediction in anticoagulated patients with atrial fibrillation. Roldán V; Vílchez JA; Manzano-Fernández S; Jover E; Gálvez J; Puche CM; Valdés M; Vicente V; Lip GY; Marín F Stroke; 2014 Mar; 45(3):696-701. PubMed ID: 24519407 [TBL] [Abstract][Full Text] [Related]
7. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy. Hijazi Z; Oldgren J; Andersson U; Connolly SJ; Ezekowitz MD; Hohnloser SH; Reilly PA; Vinereanu D; Siegbahn A; Yusuf S; Wallentin L Circulation; 2012 Apr; 125(13):1605-16. PubMed ID: 22374183 [TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial. Vinereanu D; Stevens SR; Alexander JH; Al-Khatib SM; Avezum A; Bahit MC; Granger CB; Lopes RD; Halvorsen S; Hanna M; Husted S; Hylek EM; Mărgulescu AD; Wallentin L; Atar D Eur Heart J; 2015 Dec; 36(46):3268-75. PubMed ID: 26371113 [TBL] [Abstract][Full Text] [Related]
9. Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation. Hijazi Z; Aulin J; Andersson U; Alexander JH; Gersh B; Granger CB; Hanna M; Horowitz J; Hylek EM; Lopes RD; Siegbahn A; Wallentin L; Heart; 2016 Apr; 102(7):508-17. PubMed ID: 26839066 [TBL] [Abstract][Full Text] [Related]
10. Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. Avezum A; Lopes RD; Schulte PJ; Lanas F; Gersh BJ; Hanna M; Pais P; Erol C; Diaz R; Bahit MC; Bartunek J; De Caterina R; Goto S; Ruzyllo W; Zhu J; Granger CB; Alexander JH Circulation; 2015 Aug; 132(8):624-32. PubMed ID: 26106009 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. Lopes RD; Al-Khatib SM; Wallentin L; Yang H; Ansell J; Bahit MC; De Caterina R; Dorian P; Easton JD; Erol C; Ezekowitz JA; Gersh BJ; Granger CB; Hohnloser SH; Horowitz J; Hylek EM; McMurray JJ; Mohan P; Vinereanu D; Alexander JH Lancet; 2012 Nov; 380(9855):1749-58. PubMed ID: 23036896 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial. Hu PT; Lopes RD; Stevens SR; Wallentin L; Thomas L; Alexander JH; Hanna M; Lewis BS; Verheugt FW; Granger CB; Jones WS J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28096100 [TBL] [Abstract][Full Text] [Related]
13. Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Westenbrink BD; Alings M; Granger CB; Alexander JH; Lopes RD; Hylek EM; Thomas L; Wojdyla DM; Hanna M; Keltai M; Steg PG; De Caterina R; Wallentin L; van Gilst WH Am Heart J; 2017 Mar; 185():140-149. PubMed ID: 28267467 [TBL] [Abstract][Full Text] [Related]
14. N-terminal pro-brain natriuretic peptide levels had an independent and added ability in the evaluation of all-cause mortality in older Chinese patients with atrial fibrillation. Fu S; Jiao J; Guo Y; Zhu B; Luo L BMC Geriatr; 2019 Feb; 19(1):56. PubMed ID: 30819103 [TBL] [Abstract][Full Text] [Related]
15. Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. Al-Khatib SM; Thomas L; Wallentin L; Lopes RD; Gersh B; Garcia D; Ezekowitz J; Alings M; Yang H; Alexander JH; Flaker G; Hanna M; Granger CB Eur Heart J; 2013 Aug; 34(31):2464-71. PubMed ID: 23594592 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight. Hohnloser SH; Fudim M; Alexander JH; Wojdyla DM; Ezekowitz JA; Hanna M; Atar D; Hijazi Z; Bahit MC; Al-Khatib SM; Lopez-Sendon JL; Wallentin L; Granger CB; Lopes RD Circulation; 2019 May; 139(20):2292-2300. PubMed ID: 30773022 [TBL] [Abstract][Full Text] [Related]
17. Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial. Bahit MC; Lopes RD; Wojdyla DM; Hohnloser SH; Alexander JH; Lewis BS; Aylward PE; Verheugt FW; Keltai M; Diaz R; Hanna M; Granger CB; Wallentin L Int J Cardiol; 2013 Dec; 170(2):215-20. PubMed ID: 24192334 [TBL] [Abstract][Full Text] [Related]
18. Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation. Hijazi Z; Wallentin L; Lindbäck J; Alexander JH; Connolly SJ; Eikelboom JW; Ezekowitz MD; Granger CB; Lopes RD; Pol T; Yusuf S; Oldgren J; Siegbahn A J Am Heart Assoc; 2020 Dec; 9(24):e018984. PubMed ID: 33292046 [TBL] [Abstract][Full Text] [Related]
19. Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence. Yates SW Hosp Pract (1995); 2011 Oct; 39(4):7-16. PubMed ID: 22056819 [TBL] [Abstract][Full Text] [Related]